286 related articles for article (PubMed ID: 32544408)
1. Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
Tilmanis D; Koszalka P; Barr IG; Rossignol JF; Mifsud E; Hurt AC
Antiviral Res; 2020 Aug; 180():104851. PubMed ID: 32544408
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy.
Mifsud EJ; Tilmanis D; Oh DY; Ming-Kay Tai C; Rossignol JF; Hurt AC
Antiviral Res; 2020 Apr; 176():104751. PubMed ID: 32088248
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro.
Belardo G; Cenciarelli O; La Frazia S; Rossignol JF; Santoro MG
Antimicrob Agents Chemother; 2015 Feb; 59(2):1061-9. PubMed ID: 25451059
[TBL] [Abstract][Full Text] [Related]
4. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.
Tilmanis D; van Baalen C; Oh DY; Rossignol JF; Hurt AC
Antiviral Res; 2017 Nov; 147():142-148. PubMed ID: 28986103
[TBL] [Abstract][Full Text] [Related]
5. Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.
Pizzorno A; Abed Y; Plante PL; Carbonneau J; Baz M; Hamelin MÈ; Corbeil J; Boivin G
Antimicrob Agents Chemother; 2014 Nov; 58(11):6398-405. PubMed ID: 25114143
[TBL] [Abstract][Full Text] [Related]
6. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
[TBL] [Abstract][Full Text] [Related]
7. Differential Viral-Host Immune Interactions Associated with Oseltamivir-Resistant H275Y and Wild-Type H1N1 A(pdm09) Influenza Virus Pathogenicity.
Vidaña B; Martínez-Orellana P; Martorell JM; Baratelli M; Martínez J; Migura-Garcia L; Córdoba L; Pérez M; Casas I; Pozo F; Fraile L; Majó N; Montoya M
Viruses; 2020 Jul; 12(8):. PubMed ID: 32721992
[TBL] [Abstract][Full Text] [Related]
8. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
Marjuki H; Mishin VP; Chesnokov AP; De La Cruz JA; Davis CT; Villanueva JM; Fry AM; Gubareva LV
J Virol; 2015 May; 89(10):5419-26. PubMed ID: 25740997
[TBL] [Abstract][Full Text] [Related]
9.
Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
[TBL] [Abstract][Full Text] [Related]
10. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.
Nguyen JT; Hoopes JD; Le MH; Smee DF; Patick AK; Faix DJ; Blair PJ; de Jong MD; Prichard MN; Went GT
PLoS One; 2010 Feb; 5(2):e9332. PubMed ID: 20179772
[TBL] [Abstract][Full Text] [Related]
11. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
Yu J; Wang D; Jin J; Xu J; Li M; Wang H; Dou J; Zhou C
Antiviral Res; 2016 Mar; 127():68-78. PubMed ID: 26802558
[TBL] [Abstract][Full Text] [Related]
13. Viral burden, inflammatory milieu and CD8
Nüssing S; Mifsud E; Hensen L; Koutsakos M; Wang Z; Kedzierski L; Mercuri F; Rossignol JF; Hurt AC; Kedzierska K
Influenza Other Respir Viruses; 2020 Nov; 14(6):678-687. PubMed ID: 32588557
[TBL] [Abstract][Full Text] [Related]
14. Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.
Park S; Kim JI; Lee I; Lee S; Hwang MW; Bae JY; Heo J; Kim D; Jang SI; Kim H; Cheong HJ; Song JW; Song KJ; Baek LJ; Park MS
PLoS One; 2014; 9(7):e101325. PubMed ID: 24992479
[TBL] [Abstract][Full Text] [Related]
15. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus.
Baz M; Carbonneau J; Rhéaume C; Cavanagh MH; Boivin G
Viruses; 2018 Nov; 10(11):. PubMed ID: 30400276
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
Checkmahomed L; Padey B; Pizzorno A; Terrier O; Rosa-Calatrava M; Abed Y; Baz M; Boivin G
Viruses; 2020 Oct; 12(10):. PubMed ID: 33049959
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of synergistic inhibitory effects of neuraminidase inhibitors and methylglyoxal against influenza virus infection.
Charyasriwong S; Watanabe K; Rahmasari R; Matsunaga A; Haruyama T; Kobayashi N
Arch Med Res; 2015 Jan; 46(1):8-16. PubMed ID: 25523147
[TBL] [Abstract][Full Text] [Related]
18. Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with
Cáceres CJ; Hu Y; Cárdenas-García S; Wu X; Tan H; Carnaccini S; Gay LC; Geiger G; Ma C; Zhang QY; Rajao D; Perez DR; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):1832-1848. PubMed ID: 34427541
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.
Govorkova EA; Marathe BM; Prevost A; Rehg JE; Webster RG
Antiviral Res; 2011 Aug; 91(2):81-8. PubMed ID: 21635924
[TBL] [Abstract][Full Text] [Related]
20. Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
Neri-Bazán RM; García-Machorro J; Méndez-Luna D; Tolentino-López LE; Martínez-Ramos F; Padilla-Martínez II; Aguilar-Faisal L; Soriano-Ursúa MA; Trujillo-Ferrara JG; Fragoso-Vázquez MJ; Barrón BL; Correa-Basurto J
Eur J Med Chem; 2017 Mar; 128():154-167. PubMed ID: 28182988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
